Literature DB >> 10781006

Impaired vascular sensitivity to nitric oxide in the coronary microvasculature after endotoxaemia.

R G Bogle1, P G McLean, A Ahluwalia, P Vallance.   

Abstract

1. The effects of endotoxaemia on coronary vasodilator responses to bradykinin (BK), sodium nitroprusside (SNP) and nicardipine were investigated in the rat isolated heart perfused at constant flow ex vivo. 2. Dose-dependent reductions in coronary perfusion pressure reaching a maximum of 56+/-3 and 57+/-5 mmHg were observed for BK and SNP respectively. The BK response was biphasic, consisting of a rapid dilator response that was insensitive to N(G)nitro-L-arginine methyl ester (L-NAME, 0.1 mM) and a second slower component whose duration was attenuated by L-NAME. 3. Hearts obtained from rats treated with endotoxin (2.5 mg kg(-1), i.p.) for 2 or 6 h had increased basal coronary perfusion pressure and reduced vasodilator responses to BK or SNP. Dilator responses to nicardipine were not affected by endotoxin treatment. In vitro perfusion of hearts from endotoxin-treated rats with L-NAME (0.1 mM) restored SNP responses to control values. 4. Treatment with dexamethasone (1 mg kg(-1)), 1 h before endotoxin did not alter the endotoxin-induced impairment of dilator responses to BK or SNP. 5. These results show that coronary microvascular responses are altered following endotoxin exposure. Endotoxin results in increased coronary microvascular tone despite induction of NO synthase and inhibits the dilator response to BK and SNP, vasodilators that act via the release of NO. Responses to SNP in endotoxin-treated hearts were restored to control values in the presence of L-NAME suggesting that enhanced endogenous NO synthesis might saturate guanylate cyclase resulting in reduced response to NO donors. The reduced response to vasodilators and increased coronary resistance might be important in determining the response of the coronary circulation to systemic inflammation and infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781006      PMCID: PMC1572031          DOI: 10.1038/sj.bjp.0703267

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  In vitro myocardial performance after lethal and nonlethal doses of endotoxin.

Authors:  K H McDonough; B A Brumfield; C H Lang
Journal:  Am J Physiol       Date:  1986-02

2.  Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart.

Authors:  D Fulton; J C McGiff; J Quilley
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

3.  Irreversible inhibition of cytochrome P450 by nitric oxide.

Authors:  Y Minamiyama; S Takemura; S Imaoka; Y Funae; Y Tanimoto; M Inoue
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

4.  Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis.

Authors:  M Kato; N Shiode; T Yamagata; H Matsuura; G Kajiyama
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

5.  Mechanisms of acute vasodilator response to bacterial lipopolysaccharide in the rat coronary microcirculation.

Authors:  T R Cannon; G E Mann; A R Baydoun
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

6.  Alterations of myocardial and vascular adrenergic receptor-mediated responses in Escherichia coli-induced septic shock in the rat.

Authors:  A Boillot; J Massol; V Maupoil; R Grelier; G Capellier; A Berthelot; F Barale
Journal:  Crit Care Med       Date:  1996-08       Impact factor: 7.598

7.  Endotoxin-induced inhibition of mesenteric vasodilator responses to acetylcholine, bradykinin, and post-occlusion hyperemia in anesthetized rats.

Authors:  Z Fatehi-Hassanabad; J R Parratt; B L Furman
Journal:  Shock       Date:  1996-11       Impact factor: 3.454

8.  Time course and cellular localization of lipopolysaccharide-induced inducible nitric oxide synthase messenger RNA expression in the rat in vivo.

Authors:  S F Liu; P J Barnes; T W Evans
Journal:  Crit Care Med       Date:  1997-03       Impact factor: 7.598

9.  The coronary circulation in human septic shock.

Authors:  R E Cunnion; G L Schaer; M M Parker; C Natanson; J E Parrillo
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

10.  Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.

Authors:  L C Hamilton; T D Warner
Journal:  Br J Pharmacol       Date:  1998-09       Impact factor: 8.739

View more
  5 in total

1.  Subclinical Left Ventricular Systolic Dysfunction in Patients with Septic Shock Based on Sepsis-3 Definition: A Speckle-Tracking Echocardiography Study.

Authors:  Pham Dang Hai; Le Lan Phuong; Nguyen Manh Dung; Le Thi Viet Hoa; Do Van Quyen; Nguyen Xuan Chinh; Vu Duy Minh; Pham Nguyen Son
Journal:  Crit Care Res Pract       Date:  2020-09-21

2.  Coronary blood flow becomes uncoupled from myocardial work during obstructive sleep apnea in the presence of endothelial dysfunction.

Authors:  Garun S Hamilton; Peter Solin; Adrian Walker
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

3.  Extracellular L-arginine is required for optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall.

Authors:  Andrew MacKenzie; Roger M Wadsworth
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

4.  Oroxylin a, but not vasopressin, ameliorates cardiac dysfunction of endotoxemic rats.

Authors:  Chin-Hung Liu; Mei-Fang Chen; Tzu-Ling Tseng; Lih-Geeng Chen; Jon-Son Kuo; Tony Jer-Fu Lee
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

5.  Prognostic Role of Left Ventricular Systolic Function Measured by Speckle Tracking Echocardiography in Septic Shock.

Authors:  Pham Dang Hai; Nguyen Thanh Binh; Nguyen Viet Quang Hien; Nguyen Huy Hoang; Vu Ngoc Hoan; Pham Nguyen Son; Le Thi Viet Hoa
Journal:  Biomed Res Int       Date:  2020-10-21       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.